<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111050">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02034565</url>
  </required_header>
  <id_info>
    <org_study_id>CV185-029</org_study_id>
    <nct_id>NCT02034565</nct_id>
  </id_info>
  <brief_title>Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects</brief_title>
  <official_title>Study of Bioavailability of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the oral bioavailability of Apixaban solution
      formulation (Treatment B, 10 mg as 25 mL x 0.4 mg/mL) relative to Apixaban Phase 3 tablets
      (Treatment A, 10 mg as 2 x 5 mg tablets) in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Bioavailability of Apixaban solution formulation relative to Apixaban Phase 3 tablets in healthy subjects</measure>
    <time_frame>Up to 8 Days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of Apixaban obtained from the plasma concentration versus time data</measure>
    <time_frame>32 timepoints up to Day 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of Apixaban obtained from the plasma concentration versus time data</measure>
    <time_frame>32 timepoints up to Day 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to the time of last quantifiable plasma concentration [AUC (0-T)] of Apixaban  obtained from the plasma concentration versus time data</measure>
    <time_frame>32 timepoints up to Day 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC (INF)] of Apixaban obtained from the plasma concentration versus time data</measure>
    <time_frame>32 timepoints up to Day 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma elimination half-life (T-Half) of Apixaban  obtained from the plasma concentration versus time data</measure>
    <time_frame>32 timepoints up to Day 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety analysis based on the Adverse events reports, Vital sign measurements, Electro cardiogram (ECG), physical examinations, and clinical laboratory tests</measure>
    <time_frame>Up to Day 8</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Arm A: Apixaban tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apixaban Film coated Tablet Single dose 10 mg orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Apixaban oral solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apixaban Solution Single dose 10 mg orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <arm_group_label>Arm B: Apixaban oral solution</arm_group_label>
    <arm_group_label>Arm A: Apixaban tablet</arm_group_label>
    <other_name>BMS - 562247</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects as determined by no clinically significant deviation from normal in
             medical history, physical examination, ECGs, and clinical laboratory determinations

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness or relevant trauma (e.g., history of
             chronic hypertension, bacterial endocarditis, hemorrhagic stroke, motor vehicle
             accident resulting in significant head trauma or internal injuries)

          -  History or evidence of abnormal bleeding or coagulation disorder (e.g., easy bruising
             or gingival bleeding, prolonged bleeding after dental extraction, postpartum, or
             after trauma, wounds or surgery)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MDS Pharma Services</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trials Disclosure</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 10, 2014</lastchanged_date>
  <firstreceived_date>January 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
